Key facts
- This page summarizes Barry D. Quart's Form 4 filing for Kiniksa Pharmaceuticals, Ltd. (KNSA).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 08 Jun 2023, 16:21.
Barry D. Quart - 06 Jun 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)
- Reporting relationship
- Director
- Issuer ticker
- KNSA
- Reported as of
- 06 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Jun 2023, 16:21:33 UTC
- Prior SEC filing
- 20 Jan 2023
- Next SEC filing
- 03 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Madelyn Zeylikman, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Barry D. Quart filed Form 4 for Kiniksa Pharmaceuticals, Ltd. (KNSA) on 08 Jun 2023.
Change
- Previous filing in this sequence was filed on 20 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KNSA
transaction
Derivative
Share Option
Award
- Transaction value
- $0
- Shares
- +26,236
- Change %
- Price
- $0.000000
- Shares after
- 26,236
- Date
- 06 Jun 2023
- Ownership
- Direct
- Underlying class
- Class A Common Shares
- Underlying amount
- 26,236
- Exercise price
- $15.19
- Footnotes
- F1
KNSA
transaction
Derivative
Restricted Share Units
Award
- Transaction value
- $0
- Shares
- +4,373
- Change %
- Price
- $0.000000
- Shares after
- 4,373
- Date
- 06 Jun 2023
- Ownership
- Direct
- Underlying class
- Class A Common Shares
- Underlying amount
- 4,373
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 6, 2023.
Footnote F2
Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
Footnote F3
The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023.